Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Intravesical Recombinant Mycobacterium (rMBCG)
Intravesical Recombinant Mycobacterium · 1 trial · 1 indication
Safety assessments will include demographics/medical history, vital signs, hematology, chemistry, urinalysis, and pregnancy.
| Arm | Type | Description |
|---|---|---|
| Intravesical Recombinant Mycobacterium (rMBCG) | EXPERIMENTAL | Participants will receive an induction course of 1-19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration). |
| Name | Type | Description |
|---|---|---|
| Intravesical Recombinant Mycobacterium (rMBCG) | BIOLOGICAL | 19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration) |
Inclusion Criteria: Participants must meet ALL of the following criteria for inclusion in the study: 1. Male or female participants 18 years of age or older. 2. Histologic confirmation of BCG naïve non-muscle invasive urothelial carcinoma of the bladder (mixed histology tumors allowed if urothelia...
Intravesical Recombinant Mycobacterium (rMBCG) is an investigational therapy being studied for non-muscle invasive bladder cancer (NMIBC). It is administered intravesically, meaning directly into the bladder, and is currently in Phase 1 clinical development for this indication.
Intravesical Recombinant Mycobacterium (rMBCG) is being developed by ImmunityBio, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IBRX. The company is conducting a Phase 1 clinical trial of this investigational therapy for non-muscle invasive bladder cancer.
Intravesical Recombinant Mycobacterium (rMBCG) is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for safety and efficacy in patients with non-muscle invasive bladder cancer.
Intravesical Recombinant Mycobacterium (rMBCG) is being studied in a Phase 1 clinical trial with the identifier NCT06800963, titled ResQ133A-NMIBC. This recruiting trial is enrolling approximately 40 participants with non-muscle invasive bladder cancer in the United States, with a minimum age of 18 years.
Yes, Intravesical Recombinant Mycobacterium is also known as rMBCG. The drug is referred to by both names in clinical research, and the ongoing Phase 1 trial NCT06800963 uses the rMBCG abbreviation to describe this investigational therapy for non-muscle invasive bladder cancer.